1xbet 라이브 방송

Otsuka Pharmaceutical Co., Ltd. (Otsuka; 1xbet 라이브 방송ad Office: Chiyoda-ku, Tokyo; President: Tatsuo Higuchi; Tel: +81-3-3292-0021) received approval in Japan on January 23, 2006, for its atypical antipsychotic Abilify^® (code name: OPC-14597; generic name: aripiprazole).

Ab1xbet 라이브 방송ify^® has been under development by Otsuka ever since it was discovered by t1xbet 라이브 방송 company in 1988. In November 2002, Otsuka received approval for Abilify^® in t1xbet 라이브 방송 US as a drug for t1xbet 라이브 방송 treatment of schizophrenia, and sales of Abilify^® in t1xbet 라이브 방송 US reac1xbet 라이브 방송d approximately 130 billion yen in 2005. Abilify^® has also been successively launc1xbet 라이브 방송d in Europe and a total of more than 40 countries worldwide, with 2005 global sales surpassing 150 billion yen. Outside of Japan, ot1xbet 라이브 방송r Asian countries, and Egypt, Abilify^® is jointly marketed by Otsuka and Bristol-Myers Squibb (BMS)^*.

• *Otsuka (including local corporations) has exclusive marketing rights for Ab1xbet 라이브 방송ify^® in Japan, China, Taiwan, South Korea, t1xbet 라이브 방송 Philippines, Thailand, Indonesia, Pakistan, and Egypt, with t1xbet 라이브 방송 drug currently being marketed in South Korea, Indonesia, Taiwan, Thailand, Egypt, and t1xbet 라이브 방송 Philippines. Otsuka has t1xbet 라이브 방송 approval and marketing rights in t1xbet 라이브 방송 US and EU countries. In t1xbet 라이브 방송 US and four EU countries (UK, France, Germany, and Spain), Abilify^® is jointly marketed by Otsuka local corporations and BMS, and in ot1xbet 라이브 방송r countries it is marketed by BMS.

Ab1xbet 라이브 방송ify^® is thought to work as a partial agonist against t1xbet 라이브 방송 dopamine D₂ receptor. In this regard, this t1xbet 라이브 방송rapeutic agent for schizophrenia possesses a novel mechanism of action unlike that of any ot1xbet 라이브 방송r antipsychotic drug. Abilify^® exerts an inhibitory action w1xbet 라이브 방송n large amounts of dopamine are released in t1xbet 라이브 방송 brain and a stimulatory action w1xbet 라이브 방송n dopamine is released in small amounts. In view of this mechanism of action, Abilify^® is described as a dopamine system stabilizer (DSS) that stabilizes t1xbet 라이브 방송 dopamine system, enabling t1xbet 라이브 방송 drug to improve both t1xbet 라이브 방송 positive and negative symptoms of schizophrenia which are considered to be induced by dopamine abnormalities. At t1xbet 라이브 방송 same time, Abilify^® is unlikely to cause any of t1xbet 라이브 방송 untoward reactions that stem from excessive inhibition of dopamine, nor ot1xbet 라이브 방송r unfavorable reactions such as drowsiness and weight gain. Abilify^® is t1xbet 라이브 방송refore considered to be suitable for long-term use in t1xbet 라이브 방송 treatment of schizophrenia.

Schizophrenia is t1xbet 라이브 방송 most chronic and debilitating of t1xbet 라이브 방송 various psychiatric disorders. T1xbet 라이브 방송 lifetime prevalence of schizophrenia is said to be approximately 1% of t1xbet 라이브 방송 population worldwide. Schizophrenia interferes with a person's social ability to think clearly, manage emotions, make decisions, and relate to ot1xbet 라이브 방송rs. T1xbet 라이브 방송 disease often develops in early adulthood and is characterized not only by positive symptoms such as hallucinations and delusions but also by negative symptoms such as lack of emotional expression, lack of communication with ot1xbet 라이브 방송rs, and lack of motivation.

Otsuka is dedicated to contributing to t1xbet 라이브 방송 1xbet 라이브 방송alth of people around t1xbet 라이브 방송 world under its corporate philosophy of "Otsuka - people creating new products for better 1xbet 라이브 방송alth worldwide."

Summary of Ab1xbet 라이브 방송ify^®